Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05769959 · ClinicalTrials.gov registry record · Phase 1
Study of RO7515629 in Participants With HLA-G Positive Solid Tumors
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT05769959 is a Phase 1 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 3 participants.
The verdict
NCT05769959, a Phase 1 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
Interventions
- DRUG tocilizumab
- DRUG RO7515629
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2024-03-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05769959
The ClinicalTrials.gov registry entry for NCT05769959 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which tocilizumab is the first listed.
NCT05769959 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05769959 about?
NCT05769959 is a clinical study titled "Study of RO7515629 in Participants With HLA-G Positive Solid Tumors". The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, immune response and preliminary anti-tumor activity of RO7515629 alone in participants with advanced or metastatic solid tumors expressing human leukocyte antigen G (HLA-G).
What is the current status of trial NCT05769959?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2023-06-15. Estimated completion is 2024-03-19.
What interventions are being tested in trial NCT05769959?
The interventions under investigation include: tocilizumab (DRUG), RO7515629 (DRUG).
Who is sponsoring clinical trial NCT05769959?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.